Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers

Inclusion Criteria:

- Participants with a corrected decimal visual acuity (VA) of 0.5 or better in both
eyes.

Exclusion Criteria:

- Subjects with known hypersensitivity or contraindications to latanoprostene bunod, or
any of the ingredients in the study drug.

- Subjects with known contraindications to NO treatment.

- Subjects who are unable to discontinue contact lens use at least 7 days prior to Visit
2 (Day 0/1/2) and during the 14 to 15-day study treatment period.

- Subjects who are unable to discontinue the use of all topical ophthalmic medications,
including artificial tears, at least 7 days prior to Visit 2 (Day 0/1/2) and during
the 14 to 15-day study treatment period.

- Subjects with any condition that prevents reliable applanation tonometry in either
eye.

- Subjects with glaucoma in either eye.

- Subjects with any condition that prevents clear visualization of the fundus.

- Subjects who are monocular.

- Subjects with aphakia in either eye.

- Subjects with an active corneal disease in either eye.

- Subjects with severe dry eye in either eye.

- Subjects with a history/diagnosis of a clinically significant or progressive retinal
disease in either eye.

- Subjects with any intraocular infection or inflammation within 3 months (90 days)
prior to Visit 1 (Screening).

- Subjects with a history of ocular laser surgery within the 3 months (90 days) prior to
Visit 1 (Screening).

- Subjects with a history of incisional ocular surgery or severe trauma.